Author

J. N. Burrows

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:plant (other)· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. A. Mouratidis· 1 shared A. Chakraborty· 1 shared A. Delion· 1 shared A. K. Chatterjee· 1 shared A. K. Davey· 1 shared A. K. Gupta· 1 shared A. K. Woods· 1 shared A. Karabina· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. A. Mouratidis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection

A. K. Gupta, A. M. Eliasen, W. Andahazy, F. Zhou, K. Henson, V. Chi, A. K. Woods, S. B. Joseph, K. L. Kuhen, J. Wisler, H. Ramachandruni, J. Duffy, J. N. Burrows, E. Vadas, A. Slade, , A. K. Chatterjee

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.

bioRxiv · Feb 8, 2024 · PreprintPharmacology & Toxicology

Discovery of 1,3,4-oxadiazoles with slow-action activity against Plasmodium falciparum malaria parasites

K. T. Andrews, G. M. Fisher, M. Firmin, A. Liepa, T. Wilson, J. Gardiner, Y. Mohri, A. Rai, A. K. Davey, A. Masurier, A. Delion, A. A. Mouratidis, O. Hutt, J. N. Burrows, J. H. Ryan, , T. S. Skinner-Adams

The paper identifies new antiplasmodial compounds with slow-action activity but highlights pharmacokinetic limitations for in vivo efficacy.

bioRxiv · Mar 9, 2023 · PreprintMicrobiology

A small-molecule myosin inhibitor as a targeted multi-stage antimalarial

D. V. Trivedi, A. Karabina, G. Bergnes, A. Racca, H. Wander, S. Jung, N. Mittal, T. Huijs, S. Ouchida, P. V. Ruijgrok, D. Song, S. Wittlin, P. Mukherjee, A. Chakraborty, E. A. Winzeler, , J. Spudich

This paper develops a small-molecule myosin inhibitor, KNX-115, effective against multiple stages of Plasmodium infection with high selectivity and potency.

bioRxiv · Sep 9, 2022 · PreprintPharmacology & Toxicology

Evaluation of current and emerging anti-malarial medicines for inhibition of Toxoplasma gondii growth in vitro

J. B. Radke, J. N. Burrows, D. E. Goldberg, L. D. Sibley

This study evaluates anti-malarial drugs for their ability to inhibit Toxoplasma gondii growth in vitro, finding limited effectiveness for most compounds.

bioRxiv · May 8, 2018Microbiology